|
Metamizole: Risk of drug-induced liver injury
|
|
Myfortic (mycophenolic acid): risk of teratogenicity
|
|
Actemra
|
|
Tivicay (dolutegravir): updated information on neural tube defects reported in Tsepamo Study, Botswana
|
|
Tecentriq (atezolizumab), identified risk of severe cutaneous adverse reactions (SCARs) direct healthcare professional communication (DHPC)
|
|
Cellcept (mycophenolate mopetil)
|
|
Retinoids (Isotretinoin) - update on teratogenicity and neuropsychiatric disorders Direct Healthcare
|
|
Important information about Mabthera
|
|
Important information on Dacarbazine medac 200 mg: decreased stability after reconstitution
|
|
Leuprorelin-containing depot products: need to strictly follow instructions for reconstitution and administration to reduce the risk of handling errors that may result in lack of efficacy
|
